Xencor to Present at Upcoming Investor Conferences
Xencor, a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for treating cancer and autoimmune diseases, has announced its participation in several investor events.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in the following upcoming investor events and conferences:
-
Bernstein CD28 Day
Presentation: Monday, August 9, 1:00 p.m. ET (10:00 a.m. PT)
-
2021 Wedbush PacGrow Healthcare Virtual Conference
Panel: Tuesday, August 10, 1:10 p.m. ET (10:10 a.m. PT)
-
BTIG Virtual Biotechnology Conference 2021
Presentation: Tuesday, August 10, 3:30 p.m. ET (12:30 p.m. PT)
-
Canaccord Genuity 41st Annual Growth Conference
Presentation: Wednesday, August 11, 4:30 p.m. ET (1:30 p.m. PT)
-
Piper Sandler Virtual West Coast Bus Tour
Presentation: Thursday, August 12, 4:00 p.m. ET (1:00 p.m. PT)
A webcast of the presentation at the Canaccord conference will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website approximately for at least 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005699/en/